Our Approach

Ardelyx develops:

  • Drugs that target proteins found in the gut whose activities affect the entire body
  • Drugs that are not absorbed, enabling them to achieve systemic efficacy while avoiding systemic toxicity and side effects

What we do

Targeted Therapeutic Areas

Ardelyx has established a unique approach to drug development with programs targeting gut transporters, receptors, and enzymes

Therapeutic Areas

News

Ardelyx will present at the American College of Gastroenterology Annual Scientific Meeting on October 28 - November 2, 2011 in Washington, DC


08/08/2011

 

The Safety, Tolerability, Systemic Exposure, and Effect on Bowel Habits of Single and Multiple Doses of the Intestinal Sodium Re-Uptake Inhibitor RDX5791 in Normal Healthy Volunteers. Rosenbaum, David P; Spencer, Andrew G.; Jacobs, Jeffrey W.; Charmot, Dominique, Ardelyx, Inc., Fremont, CA, United States 



« back to news page